^
Association details:
| Biomarker: | NF1 mutation |
|---|---|
| Cancer: | Neurofibrosarcoma |
| Drug: | mercaptopurine delayed release (DR6MP) (Nerve growth factor inhibitor) + JHU395 (Glutamine antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1293 - A novel protide purine antimetabolite combines with the prodrug glutamine antagonist JHU395 in preclinical models of Ras-driven sarcomas
Published date:
03/10/2021
Excerpt:
We therefore investigated the combination of the purine antimetabolite 6-mercaptopurine (6-MP) with JHU395 in NF1-mutant malignant peripheral nerve sheath tumor (MPNST) models. 6-MP (10 micromolar) inhibited growth of human MPNST cells as a single agent and in combination with low dose JHU395 (1 micromolar).
